Examining the Pharmaceutical Supply Chain: From Production to Patient

On November 14, 2017, RealClearPolitics—in partnership with The Value Collaborative—brought together a cross-section of experts to examine the biopharmaceutical supply chain. Panelists explained the distinct roles that make up the supply chain, analyzed the factors that contribute to the price consumers pay for their medicines and identified steps that can be taken to bring greater value to consumers.


  • Adam Fein, president, Pembroke Consulting
  • Doug Hoey, CEO, National Community Pharmacists Association
  • Cheryl Larson, incoming president, Midwest Business Group on Health
  • Mark Merritt, president and CEO, Pharmaceutical Care Management Association
  • Lori Reilly, executive vice president for policy, research and membership, PhRMA
  • Jim Sheninger, chief pharmacy officer, GoodRx
  • Senator Steve Sweeney, president, New Jersey State Senate


  • Tom Bevan, co-founder and publisher, RealClearPolitics
  • Tony Mills, editor, RealClearPolicy
  • Erin Waters, president, RealClear Media Group